Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:AVIR

Atea Pharmaceuticals Q1 2025 Earnings Report

Atea Pharmaceuticals logo
$4.98 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.92 -0.06 (-1.10%)
As of 07/2/2026 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Atea Pharmaceuticals EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Atea Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atea Pharmaceuticals Announcement Details

Quarter
Q1 2025
Date
5/12/2025
Time
After Market Closes
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Atea Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Atea Pharmaceuticals' Q1 2025 Press ReleasePress Release
(8-K)
Atea Pharmaceuticals' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Atea Pharmaceuticals Earnings Headlines

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317395/0/en/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-evaluating-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus.html
Atea Shareholders Back Directors, Auditors and Executive Pay
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/atea-shareholders-back-directors-auditors-and-executive-pay?utm_source=marketbeat.com&utm_medium=referral
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
July 4 at 1:00 AM  |  Reagan Gold Group (Ad)
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
May 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4910058-atea-pharmaceuticals-im-optimistic-ahead-of-critical-hpv-catalyst
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of ...
May 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-1036197628
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
May 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/27/3301752/0/en/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatit.html
See More Atea Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atea Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your email.

About Atea Pharmaceuticals

Atea Pharmaceuticals (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization.

Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.

View Atea Pharmaceuticals Profile
Earnings Tools